首页> 外文OA文献 >Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

【2h】

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

机译：慢性粒细胞白血病的老年患者（≥65岁）比年轻患者受益于更高的伊马替尼剂量获益更多：随机CML研究IV的亚分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Proetel Ulrike; Pletsch Nadine; Lauseker Michael; Müller Martin C.; Hanfstein Benjamin; Krause Stefan W.; Kalmanti Lida; Schreiber Annette; Heim Dominik; Baerlocher Gabriela M.; Hofmann Wolf-Karsten; Lange Elisabeth; Einsele Hermann; Wernli Martin; Kremers Stephan; Schlag Rudolf; Müller Lothar; Hänel Mathias; Link Hartmut; Hertenstein Bernd; Pfirrmann Markus; Hochhaus Andreas; Hasford Joerg; Hehlmann Rüdiger; Saußele Susanne;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: A subanalysis of the randomized CML-Study IV [J] . ProetelU., PletschN., LausekerM., Annals of hematology . 2014,第7期

机译：年龄较大的慢性粒细胞白血病（≥65岁）患者从伊马替尼剂量更高的获益要比年轻的患者更多：随机CML研究IV的亚分析
2. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. [J] . Rüdiger Hehlmann, Martin C Müller, Michael Lauseker, Journal of Clinical Oncology . 2014,第5期

机译：大多数用伊马替尼治疗的患者达到了深度分子反应，预测存活率，通过优化的高剂量伊替尼可以更快地实现：来自随机CML-SHOUL IV的结果。
3. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: A randomized phase III trial of the Dutch-Belgian HOVON study group [J] . ThielenN., VanDerHoltB., VerhoefG.E.G., Annals of hematology . 2013,第8期

机译：大剂量伊马替尼与大剂量伊马替尼联合中剂量阿糖胞苷治疗首例慢性髓样白血病的患者：荷兰-比利时HOVON研究组的一项随机III期试验
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV [O] . Ulrike Proetel, Nadine Pletsch, Michael Lauseker, -1

机译：慢性粒细胞白血病的老年患者（≥65岁）比年轻患者受益于更高的伊马替尼剂量获益更多：随机CML研究IV的亚分析
7. Older patients with chronic myeloid leukemia (>=65 years) profit more from higher imatinib doses than younger patients : a subanalysis of the randomized CML-Study IV [O] . Proetel, Ulrike, Pletsch, Nadine, Hofmann, Wolf-Karsten, 2014

机译：年龄较大的慢性粒细胞白血病（> = 65岁）患者从伊马替尼剂量更高的获益要比年轻患者更多：一项随机CML-研究IV的亚分析

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

著录项

相似文献

相关主题

期刊订阅